Pharvaris HAE drug hits 83% attack rate cut in phase 3 trial

Go back to Pharvaris HAE drug hits 83% attack rate cut in phase 3 trial
(NASDAQ: PHVS) Delayed: 36.37 -1.63 (4.29%)
Previous Close $38.00    52 Week High
Open $38.09    52 Week Low
Day High $38.20    P/E N/A 
Day Low $36.08    EPS
Volume 580,259